

## UNITED STATES PARTMENT OF COMMERCE United Stat s Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231

APPLICATION NO.	FILING DATE	FIRST NAMED IN	FIRST NAMED INVENTOR		TORNEY DOCKET NO.
09/602,50	3 06/23/0	O BONNER-WEIR		<i>::</i>	10276-029001
		HM22/0702	一	EX	AMINER
P. LOUIS MEYER				AFREMOVA, V	
FISH & RICHARDSON P.C.				ART UNIT	PAPER NUMBER
	_IN STREET 02110-2804			1651	6
				DATE MAILED:	07/02/01

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trad marks

4	Application No.	Applicant(s)					
Office Action Summary	09/602,508	BONNER-WEIR ET AL.					
Office Action Gammary	Examiner	Art Unit					
	Vera Afremova	1651					
The MAILING DATE of this communication ap	pears on the cover sheet with the co	orrespondenc address					
Period for Reply  A SHORTENED STATUTORY PERIOD FOR REP	IVIS SET TO EYDIDE 1 MONTH	(S) FROM					
THE MAILING DATE OF THIS COMMUNICATION  - Extensions of time may be available under the provisions of 37 CFR after SIX (6) MONTHS from the mailing date of this communication.  - If the period for reply specified above is less than thirty (30) days, a re  - If NO period for reply is specified above, the maximum statutory perior  - Failure to reply within the set or extended period for reply will, by status  - Any reply received by the Office later than three months after the mail earned patent term adjustment. See 37 CFR 1.704(b).  Status		mely filed s will be considered timely. the mailing date of this communication. D (35 U.S.C. § 133).					
1) Responsive to communication(s) filed on 22	<u> December 2000</u> .						
2a)☐ This action is <b>FINAL</b> . 2b)⊠ <sup>-</sup>	This action is non-final.						
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.							
Disposition of Claims							
4)⊠ Claim(s) <u>1-28</u> is/are pending in the applicati	on.						
4a) Of the above claim(s) is/are withdo	awn from consideration.						
5) Claim(s) is/are allowed.							
6)☐ Claim(s) is/are rejected.							
7) ☐ Claim(s) is/are objected to.							
8)⊠ Claims <u>1-28</u> are subject to restriction and/or election requirement.							
Application Papers							
9) The specification is objected to by the Examiner.							
10) The drawing(s) filed on is/are objected to by the Examiner.							
11) ☐ The proposed drawing correction filed on is: a) ☐ approved b) ☐ disapproved.							
12) The oath or declaration is objected to by the	Examiner.						
Priority under 35 U.S.C. § 119							
13) Acknowledgment is made of a claim for fore	ign priority under 35 U.S.C. <b>§</b> 119(	a)-(d) or (f).					
a) All b) Some * c) None of:							
1. Certified copies of the priority documents have been received.							
2. Certified copies of the priority documents have been received in Application No							
Copies of the certified copies of the particular application from the International     See the attached detailed Office action for a leading section.	Bureau (PCT Rule 17.2(a)).						
14) Acknowledgement is made of a claim for do	mestic priority under 35 U.S.C. § 1	19(e).					
Attachment(s)							
15) Notice of References Cited (PTO-892) 16) Notice of Draftsperson's Patent Drawing Review (PTO-948) 17) Information Disclosure Statement(s) (PTO-1449) Paper Not	19) Notice of Inform	ary (PTO-413) Paper No(s) al Patent Application (PTO-152)					

Application/Control Number: 09/602,508

Art Unit: 1651

## **DETAILED ACTION**

Claims 1-28 are pending and subject to restriction requirement.

## Election/Restrictions

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- I. Claims 1-13, drawn to a method for promoting dedifferentiation of pancreatic cells, classified in class 435, subclass 377, for example.
- II. Claims 14-26, drawn to a method for obtaining pancreatic islets cells, classified in class 435, subclass 325, for example.
- III. Claims 27, drawn to a method for providing islet cells, classified in class 435, subclass 373, for example.
- IV. Claim 28, drawn to a method of treating a subject having pancreatic disorder, classified in class 424, subclass 9.1, for example.

The inventions are distinct, each from the other because of the following reasons:

The inventions of Groups I, II and III are distinct because they are directed to different method comprising different active steps of obtaining, contacting and proliferating different cells and components. The inventions of Groups I -III and the invention of Group IV are distinct because they are directed to different method drawn to an *in vitro* application and an *in vivo* administration various pancreatic cells. The claimed methods have acquired a separate status in the art as shown by their different classification, they are drawn to recognized divergent subject matters and the search required for Group I is not related or required for Group II or Group III. And the in vivo and in vitro methods as intended would require consideration of distinct protocols of applications and/or administrations with regard to sites of applications, to

Page 3

SANDRA E. SAUCIER

Application/Control Number: 09/602,508

Art Unit: 1651

subject/cells under treatment, to dosages, to effects, etc. Thus, restriction for examination purposes as indicated is proper.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a petition under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Vera Afremova whose telephone number is (703) 308-9351.

The examiner can normally be reached on 9.30 am - 6.00 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Michael Wityshyn can be reached on (703) 308-4743. The fax phone numbers for the organization where this application or proceeding is assigned are (703) 308-4242 for regular communications and (703) 308-4242 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-0196.

June 28, 2001

V.A.